Truist Securities Maintains Hold on Integra Lifesciences, Raises Price Target to $19
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Truist Securities analyst Ravi Misra maintains Integra Lifesciences (NASDAQ:IART) with a Hold and raises the price target from $14 to $19.
Truist Securities analyst Ravi Misra maintains Integra Lifesciences (NASDAQ:IART) with a Hold and raises the price target from $14 to $19.